



CLL
PATIENT
ADVOCACY
GROUP

E-Bulletin

March 2017

CLLPAG UPDATE - ISSUE 8

CLLPAG Has New LOGOS



CLL PATIENT
ADVOCACY GROUP
GROUPE DE DÉFENSE DES
PATIENTS DE LA **LLC**



GROUPE DE
DÉFENSE DES
PATIENTS DE
LA **LLC**

DrugApproval News:

Imbruvica (ibrutinib) First Line - pCODR has recommended the provinces and territories fund this. As of January 5, 2017, the provinces and territories are in negotiation with the manufacturer regarding cost.

https://www.cadth.ca/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-ctl-sll-preun.pdf

INESSS (Quebec) has decided not to fund Imbruvica (ibrutinib) for first line treatment https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Fevrier_2017/
Check out cllpag.ca for updates.

Venclexta (venetoclax) - the manufacturer withdrew their application on December 15, 2016 as the initial recommendation did not recommend funding. <https://www.cadth.ca/venclexta-chronic-lymphocytic-leukemia-details>

Lymphoma Canada has released their latest book 'Understanding CLL/SLL' in English and French. Contact LC at <http://www.lymphoma.ca/resource-order-form> to order a copy.

Welcome to our newest CLLPAG Board Directors

Judy Watt-Watson - Ontario and Kathy Green - Nova Scotia

Sub-Cutaneous ImmunoGlobulin (SCIG) — is now available in BC, MB and ON. Talk to your hematologist if you are receiving IVIg would and like to try to self administer at home.

[Unsubscribe from this list](#)

For more info: cllpag.ca